Navigation Links
First-ever Compounds To Target Only Metastatic Cells Are Highly Effective Against Breast, Prostate, And Colon Cancers

to something more potent. In collaboration with the laboratory of Dr. Samuel Danishefsky at the Memorial Sloan-Kettering Cancer Center, the team went to work creating what's called a "synthetic analogue."

"Starting with the basic migrastatin molecule, we cut a piece there, add a piece here," he explained, "and what we ended up with were two compounds -- core macroketone and core macrolactam -- that are about 1,000 times more powerful at inhibiting cancer cell migration."

In fact, in a mouse model, the analogues were between 91 to 99 percent effective in stopping the spread of breast cancer cells, the researchers report. Cell culture studies suggest they can reproduce that success in a wide range of other cancers, too.

"What's unique about these analogues is that they do all this without affecting primary tumor cells, or their blood supply," Dr. Huang said. "To our knowledge, that's a real first."

Exact mechanisms remain unclear.

"Obviously, these compounds are targeting some step in the cell-migration process," Dr. Huang said. The activity of a migration-linked protein called Rac appears to be much reduced in cancer cells affected by the analogues, and the researchers also noticed that malignant cells failed to grow tiny "antennas," called lamellipodia, another crucial step in the migration process.

"Therefore, the migrastatin analogues must be working on something upstream of those two important steps," Dr. Huang said.

Dr. HuangÕs next important step is moving these analogues into clinical trials.

"We're trying right now to get a company interested in this, especially because the mice used in our trial seemed to experience minimal toxicity -- a good sign that patients might tolerate these compounds, too," Dr. Huang said.

"It's all very exciting," he said. "Metastatic disease is such a tough problem, and these compounds could provide patients with a brand new kind of hope."

The research
'"/>

Source:Cornell University


Page: 1 2 3

Related biology news :

1. First-ever genomic test predicts which lung cancer patients need chemotherapy to live
2. Compounds in plastic packaging act as environmental estrogens altering breast genes
3. Novel Enzyme Shows Potential As An Anti-HIV Target
4. Potential Drug Target For Treating Cocaine Abuse Found
5. Affymetrix and ParAllele Launch Industrys Most Comprehensive Product Line for Targeted Genotyping
6. Targeting a key enzyme with gene therapy reversed course of Alzheimers disease in mouse models
7. New Therapeutic Target Identified In Inherited Brain Tumor Disorder
8. Targeted drug delivery achieved with nanoparticle-aptamer bioconjugates
9. Targeted virus compels cancer cells to eat themselves
10. Best of both worlds -- Targeting a single gene could inhibit bone decay and stimulate bone growth
11. Targeting tumors the natural way
Post Your Comments:
Breaking Biology News(10 mins):From fruit fly wings to heart failure -- why Not(ch)? 2IGC scientist receives prestigious EMBO installation grant 2Uniform analyses for clean drinking water in Europe 2Latest analysis confirms suboptimal vitamin D levels in millions of US children 10517 1Latest analysis confirms suboptimal vitamin D levels in millions of US children 10517 2Positive Data from Arena Pharmaceuticals Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Gly 60041 1Positive Data from Arena Pharmaceuticals Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Gly 60041 2Positive Data from Arena Pharmaceuticals Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Gly 60041 3Positive Data from Arena Pharmaceuticals Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Gly 60041 4Positive Data from Arena Pharmaceuticals Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Gly 60041 5Positive Data from Arena Pharmaceuticals Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Gly 60041 6Positive Data from Arena Pharmaceuticals Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Gly 60041 7Positive Data from Arena Pharmaceuticals Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Gly 60041 8UC San Diego researchers reverse pulmonary arterial hypertension in mouse models 60038 1UC San Diego researchers reverse pulmonary arterial hypertension in mouse models 60038 2